Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Perfluoroalkyl substances (PFAS) have been linked with a number of developmental, reproductive, hepatic, and cardiovascular health outcomes. However, the evidence for an association between PFAS and hypertensive disorders of pregnancy (including gestational hypertension and preeclampsia) is equivocal and warrants further investigation. OBJECTIVES: To examine the relationship between background levels of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) and the development of gestational hypertension or preeclampsia in a Canadian pregnancy cohort. We also explored the potential for effect modification according to fetal sex. METHODS: Maternal plasma samples were collected in the first trimester from participants in the MIREC study and were analyzed for PFOA, PFOS, and PFHxS. Blood pressure was measured during each trimester. Gestational hypertension and preeclampsia were defined using the Society of Obstetricians and Gynaecologists of Canada guidelines. Logistic regression models were used to derive adjusted odds ratios (OR) and 95% confidence intervals (CI) for associations between PFAS concentrations (per doubling of concentration as well as according to tertiles) and gestational hypertension or preeclampsia. Linear mixed models were used to examine the association between PFAS concentrations and changes in blood pressure throughout pregnancy. RESULTS: Data from 1739 participants were analyzed. 90% of women were normotensive throughout pregnancy, 7% developed gestational hypertension without preeclampsia, and 3% developed preeclampsia. In the full analyses, neither PFOA nor PFOS were associated with gestational hypertension or preeclampsia. However, each doubling of PFHxS plasma concentration was associated with higher odds of developing preeclampsia (OR = 1.32; 95% CI: 1.03, 1.70). In addition, participants in the highest PFHxS tertile (1.4-40.0 μg/L) had higher odds of developing preeclampsia relative to those in the lowest tertile (OR = 3.06; 95% CI: 1.27, 7.39). In stratified analyses, this effect was only apparent among women carrying a female fetus (OR = 4.90; 95% CI: 1.02, 22.3). However, among women carrying a male fetus, both PFOS and PFHxS were associated with gestational hypertension, but not preeclampsia. Higher plasma concentrations of all three PFAS were associated with increases in diastolic blood pressure throughout pregnancy, and PFOA and PFHxS were also associated with systolic blood pressure. Discrepant findings were similarly revealed in analyses stratified by fetal sex. CONCLUSIONS: Higher levels of PFHxS were associated with the development of preeclampsia, but not gestational hypertension. Neither PFOA nor PFOS were associated with either outcome. However, we show, for the first time, that fetal sex may modify these associations, a finding which warrants replication and further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792 · cited 1×
“Missing covariate data were replaced using multiple imputation (Rubin, 1987) (PROC MI, m = 5) (White et al., 2011).”
MethodBuck, R. C., Franklin, J., Berger, U., Conder, J. M., Cousins, I. T., de Voogt, P., Jensen, A. A., Kannan, K., Mabury, S. A., & van Leeuwen, S. P. (2011) · Integrated Environmental Assessment and Management · doi:10.1002/ieam.258 · Cited by 4,641
Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings
Lau, C., Anitole, K., Hodes, C., Lai, D., Pfahles-Hutchens, A., & Seed, J. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm128 · Cited by 2,620
Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., Butenhoff, J. L., & Zobel, L. R. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10009 · Cited by 2,049
Calafat, A. M., Wong, L.-Y., Kuklenyik, Z., Reidy, J. A., & Needham, L. L. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10598 · Cited by 1,247
Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries
Kannan, K., Corsolini, S., Falandysz, J., Fillmann, G., Kumar, K. S., Loganathan, B. G., Mohd, M. A., Olivero, J., Wouwe, N. V., Yang, J. H., et al. (2004) · Environmental Science & Technology · doi:10.1021/es0493446 · Cited by 1,056
Trends in Exposure to Polyfluoroalkyl Chemicals in the U.S. Population: 1999−2008
Kato, K., Wong, L.-Y., Jia, L. T., Kuklenyik, Z., & Calafat, A. M. (2011) · Environmental Science & Technology · doi:10.1021/es1043613 · Cited by 777 · cited 3×
“…in the US is thought to have contributed to observed declines in population levels of PFOS and PFOA (Calafat et al., 2007; Glynn et al., 2012; Kato et al., 2011); however, temporal trends for other PFAS (including PFHxS) are less consistent and in some cases increases have been observed…”
BackgroundThe toxicology of perfluorooctanoate
Kennedy, G. L., Butenhoff, J. L., Olsen, G. W., O'Connor, J. C., Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., & Farrar, D. G. (2004) · Critical Reviews in Toxicology · doi:10.1080/10408440490464705 · Cited by 742
Accumulation of perfluoroalkyl substances in human tissues
Pérez, F., Nadal, M., Navarro-Ortega, A., Fàbrega, F., Domingo, J. L., Barceló, D., & Farré, M. (2013) · Environment International · doi:10.1016/j.envint.2013.06.004 · Cited by 730
Estimating Consumer Exposure to PFOS and PFOA
Trudel, D., Horowitz, L., Wormuth, M., Scheringer, M., Cousins, I. T., & Hungerbühler, K. (2008) · Risk Analysis · doi:10.1111/j.1539-6924.2008.01017.x · Cited by 514
Research works printed but not linked: 53
- American College of Obstetricians and Gynecologists, 2002, Diagnosis and management of preeclampsia and eclampsia, Int. J. Gynaecol. Obstet., 77, 67, 10.1016/S0020-7292(02)80002-9 · DOI · Paper page
- Andersen, 2010, Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy, Am. J. Epidemiol., 172, 1230, 10.1093/aje/kwq289 · DOI · Paper page
- Arbuckle, 2013, Cohort profile: the maternal-infant research on environmental chemicals research platform, Paediatr. Perinat. Epidemiol., 27, 415, 10.1111/ppe.12061 · DOI · Paper page
- Ashley-Martin, 2016, Maternal and neonatal levels of perfluoroalkyl substances in relation to gestational weight gain, Int. J. Environ. Res. Public Health, 13, 10.3390/ijerph13010146 · DOI · Paper page
- Bach, 2015, Perfluoroalkyl and polyfluoroalkyl substances and human fetal growth: A systematic review, Crit. Rev. Toxicol., 45, 53, 10.3109/10408444.2014.952400 · DOI · Paper page
- Beesoon, 2012, Exceptionally high serum concentrations of perfluorohexanesulfonate in a Canadian family are linked to home carpet treatment applications, Environ. Sci. Technol., 46, 12960, 10.1021/es3034654 · DOI · Paper page
- Berg, 2014, Maternal serum concentrations of per- and polyfluoroalkyl substances and their predictors in years with reduced production and use, Environ. Int., 69, 58, 10.1016/j.envint.2014.04.010 · DOI · Paper page
- Brantsæter, 2013, Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women, Environ. Int., 54, 74, 10.1016/j.envint.2012.12.014 · DOI · Paper page
- Butalia, 2018, Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy, Can. J. Cardiol., 34, 526
- Butenhoff, 2009, Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats, Reprod. Toxicol., 27, 331, 10.1016/j.reprotox.2009.01.004 · DOI
- Chappell, 2020, Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks, Toxicol. Pathol., 10.1177/0192623320905803 · DOI · Paper page
- Darrow, 2013, Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005–2010, Environ. Health Perspect., 121, 1207, 10.1289/ehp.1206372 · DOI · Paper page
- Desquilbet, 2010, Dose-response analyses using restricted cubic spline functions in public health research, Statist. Med., 10.1002/sim.3841 · DOI · Paper page
- DiGiuseppe, 2002, Reliability of birth certificate data: a multi-hospital comparison to medical records information, Matern. Child Health J., 6, 169, 10.1023/A:1019726112597 · DOI · Paper page
- Fei, 2007, Perfluorinated chemicals and fetal growth: a study within the Danish national birth cohort, Environ. Health Perspect., 115, 1677, 10.1289/ehp.10506 · DOI · Paper page
- Fisher, 2016, Concentrations of persistent organic pollutants in maternal and cord blood from the maternal-infant research on environmental chemicals (MIREC) cohort study, Environ. Heal., 15, 59, 10.1186/s12940-016-0143-y · DOI · Paper page
- Fisher, 2013, Do perfluoroalkyl substances affect metabolic function and plasma lipids?—Analysis of the 2007–2009, Canadian Health Measures Survey (CHMS) Cycle 1, Environ. Res., 121, 95, 10.1016/j.envres.2012.11.006 · DOI
- Haines, 2017, Human biomonitoring reference values derived for persistent organic pollutants in blood plasma from the Canadian Health Measures Survey 2007–2011, Int. J. Hyg. Environ. Health, 220, 744, 10.1016/j.ijheh.2017.03.004 · DOI
- Houde, 2006, Biological monitoring of polyfluoroalkyl substances: a review, Environ. Sci. Technol., 40, 3463, 10.1021/es052580b · DOI · Paper page
- Hu, 2018, Can profiles of poly- and Perfluoroalkyl substances (PFASs) in human serum provide information on major exposure sources?, Environ. Health, 17, 11, 10.1186/s12940-018-0355-4 · DOI · Paper page
- Huang, 2019, Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy, Environ. Health, 18, 5, 10.1186/s12940-018-0445-3 · DOI · Paper page
- Huppertz, 2008, Placental origins of preeclampsia: challenging the current hypothesis, Hypertension (Dallas, Tex. 1979), 51, 970, 10.1161/HYPERTENSIONAHA.107.107607 · DOI · Paper page
- Huppertz, 2003, Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation, Placenta, 24, 181, 10.1053/plac.2002.0903 · DOI · Paper page
- Jain, 2019, Perfluoroalkyl acids serum concentrations and their relationship to biomarkers of renal failure: Serum and urine albumin, creatinine, and albumin creatinine ratios across the spectrum of glomerular function among US adults, Environ. Res., 174, 143, 10.1016/j.envres.2019.04.034 · DOI · Paper page
- Jelin, 2009, Early-onset preeclampsia and neonatal outcomes, J. Matern. Neonatal Med., 23, 1
- Kärrman, 2006, Levels of 12 perfluorinated chemicals in pooled australian serum, collected 2002–2003, in relation to age, gender, and region, Environ. Sci. Technol., 40, 3742, 10.1021/es060301u · DOI · Paper page
- Lau, 2006, Effects of perfluorooctanoic acid exposure during pregnancy in the mouse, Toxicol. Sci., 90, 510, 10.1093/toxsci/kfj105 · DOI · Paper page
- Lewin, 2017, Univariate predictors of maternal concentrations of environmental chemicals: The MIREC study, Int. J. Hyg. Environ. Health, 220, 77, 10.1016/j.ijheh.2017.01.001 · DOI
- Lin, 2010, Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults, Am. J. Gastroenterol., 105, 1354, 10.1038/ajg.2009.707 · DOI · Paper page
- Liu, 2019, Structure-based investigation on the association between perfluoroalkyl acids exposure and both gestational diabetes mellitus and glucose homeostasis in pregnant women, Environ. Int., 127, 85, 10.1016/j.envint.2019.03.035 · DOI · Paper page
- Lo, 2013, Hypertensive disease of pregnancy and maternal mortality, Curr. Opin. Obstet. Gynecol., 25, 124, 10.1097/GCO.0b013e32835e0ef5 · DOI · Paper page
- Magee, 2014, Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens, Int. J. Women’s Cardiovasc. Heal., 4, 105
- Nakimuli, 2016, The burden of maternal morbidity and mortality attributable to hypertensive disorders in pregnancy: a prospective cohort study from Uganda, BMC Pregnancy Childbirth, 16, 205, 10.1186/s12884-016-1001-1 · DOI
- Nolan, 2010, Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluorooctanoic acid (PFOA)-contaminated public drinking water, Reprod. Toxicol., 29, 147, 10.1016/j.reprotox.2009.10.012 · DOI · Paper page
- Papadopoulou, 2015, Reliability of perfluoroalkyl substances in plasma of 100 women in two consecutive pregnancies, Environ. Res., 140, 421, 10.1016/j.envres.2015.04.022 · DOI · Paper page
- Pijnenborg, 2006, The uterine spiral arteries in human pregnancy: facts and controversies, Placenta, 27, 939, 10.1016/j.placenta.2005.12.006 · DOI · Paper page
- Rosen, 2017, PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling, Toxicology, 387, 95, 10.1016/j.tox.2017.05.013 · DOI · Paper page
- Savitz, 2012, Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community, Epidemiology, 23, 386, 10.1097/EDE.0b013e31824cb93b · DOI · Paper page
- Savitz, 2012, Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio valley, Environ. Health Perspect., 120, 1201, 10.1289/ehp.1104752 · DOI · Paper page
- Shen, 2017, Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia, PLoS One, 12, e0175914, 10.1371/journal.pone.0175914 · DOI · Paper page
- Starling, 2014, Perfluoroalkyl substances during pregnancy and validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort Study, Am. J. Epidemiol., 179, 824, 10.1093/aje/kwt432 · DOI · Paper page
- Steegers, 2010, Pre-eclampsia, Lancet, 376, 631, 10.1016/S0140-6736(10)60279-6 · DOI · Paper page
- Stein, 2009, Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome, Am. J. Epidemiol., 170, 837, 10.1093/aje/kwp212 · DOI · Paper page
- Stuart, 2013, Maternal recall of hypertensive disorders in pregnancy: a systematic review, J. Women’s Health, 22, 37, 10.1089/jwh.2012.3740 · DOI · Paper page
- Sundström, 2012, Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys, Reprod. Toxicol., 33, 441, 10.1016/j.reprotox.2011.07.004 · DOI · Paper page
- van Esch, 2017, Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity, J. Matern. Neonatal Med., 30, 2789, 10.1080/14767058.2016.1263295 · DOI
- Vatten, 2004, Offspring sex and pregnancy outcome by length of gestation, Early Hum. Dev., 76, 47, 10.1016/j.earlhumdev.2003.10.006 · DOI · Paper page
- Velez, 2015, Maternal exposure to perfluorinated chemicals and reduced fecundity: the MIREC study, Hum. Reprod., 30, 701, 10.1093/humrep/deu350 · DOI · Paper page
- Wallis, 2008, Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004, Am. J. Hypertens., 21, 521, 10.1038/ajh.2008.20 · DOI · Paper page
- Wang, 2019, Efficiency of maternal-fetal transfer of perfluoroalkyl and polyfluoroalkyl substances, Environ. Sci. Pollut. Res., 26, 2691, 10.1007/s11356-018-3686-3 · DOI
- Wikström, 2019, Maternal serum levels of perfluoroalkyl substances in early pregnancy and offspring birth weight, Pediatr. Res., 1
- Wikström, 2019, Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women, Sci. Rep., 9, 9179, 10.1038/s41598-019-45483-7 · DOI · Paper page
- Ying, 2018, Hypertensive disorders of pregnancy and future maternal cardiovascular risk, J. Am. Heart Assoc., 7, e009382, 10.1161/JAHA.118.009382 · DOI · Paper page
Cited by
Fenton, S. E., Ducatman, A., Boobis, A., DeWitt, J. C., Lau, C., Ng, C., Smith, J. S., & Roberts, S. M. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4890 · Cited by 2,445
Podder, A., Sadmani, A. H. M. A., Reinhart, D., Chang, N.-B., & Goel, R. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.126361 · Cited by 623
Preston, E. V., Hivert, M.-F., Fleisch, A. F., Calafat, A. M., Sagiv, S. K., Perng, W., Rifas-Shiman, S. L., Chavarro, J. E., Oken, E., Zota, A. R., et al. (2022) · Environment International · doi:10.1016/j.envint.2022.107335 · Cited by 78
Bommarito, P. A., Ferguson, K. K., Meeker, J. D., McElrath, T. F., & Cantonwine, D. E. (2021) · Environmental Health Perspectives · doi:10.1289/ehp9091 · Cited by 70
Svoboda, L. K., Ishikawa, T., & Dolinoy, D. C. (2022) · Environmental Epigenetics · doi:10.1093/eep/dvac017 · Cited by 27
“PFAS exposures during pregnancy are also associated with an increased risk of hypertension or preeclampsia [159, 160], with differences observed based on the sex of the fetus [160].”
Background
Metadata
- Authors
- Borghese, M. M., Walker, M., Helewa, M. E., Fraser, W. D., & Arbuckle, T. E.
- Venue
- Environment International
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 141
- Pages
- 105789
- ISSN
- 0160-4120 (ISSN-L)
- OpenAlex
- W3022808302
- Cited by
- 79
- References
- 15
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Canadian Institutes of Health Research
- Health Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study. https://app.cochat.ai/papers/10.1016/j.envint.2020.105789
- The paper
- Borghese, M. M., Walker, M., Helewa, M. E., Fraser, W. D., & Arbuckle, T. E. (2020). Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study. Environment International. https://doi.org/10.1016/j.envint.2020.105789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.